世界の医療・医薬品産業レポート

TOP  >  作用機序別レポート  >  Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - パイプラインレビュー 2018年上半期

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - パイプラインレビュー 2018年上半期
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018

レポートタイトル Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - パイプラインレビュー 2018年上半期
出版社名 Global Markets Direct
発刊日 2018-04-10
体裁 PDF / 121 ページ
シングルユーザ価格 US$ 3,500
レポート分類 作用機序別レポート
地域 グローバル
領域 -
疾患名 -
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記の作用機序を標的とした治療薬パイプラインについての詳細な分析、該当作用機序についての包括的な情報、標的とする治療薬、および適応症、開発段階、作用機序(MoA)、投与方法(RoA)や分子タイプについての分析を提供します。
また、開発の歴史、最新のニュース、プレスリリースについても取り上げます。
さらに、開発中、開発中止プロジェクトの治療薬に関わる主要企業の概要も提供します。
また、該当作用機序の治療薬開発に関わる主要企業概要、開発中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development
Argos Therapeutics Inc
Asterias Biotherapeutics Inc
e-Therapeutics Plc
F. Hoffmann-La Roche Ltd
Inovio Pharmaceuticals Inc
Invectys SA
Johnson & Johnson
Komipharm International Co Ltd
Mediolanum farmaceutici SpA
Telocyte LLC
TILT Biotherapeutics Ltd
Ultimovacs AS
Vaxon Biotech
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles
AGS-499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dendritic Cell Therapy + TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETS-2300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Alzheimer's Disease and Pulmonay Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Alzheimer’s Disease and Atherosclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TERT for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imetelstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KML-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ribovax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rocapuldencel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Telomerase for Lung Cancer and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Telomerase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCPVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Telomerase for Cervical Cancer and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones
Featured News & Press Releases
Mar 24, 2018: New Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models
Jan 30, 2018: CNIO researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres
Jan 04, 2018: Asterias Biotherapeutics Provides Update on ASTVAC-2
Dec 19, 2017: PharmaJet and Invectys Partner in Phase II Clinical Trial of DNA Cancer Vaccine
Dec 12, 2017: Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
Nov 27, 2017: Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
Nov 20, 2017: Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
Nov 11, 2017: Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
Nov 10, 2017: Inovio Pharmaceuticals Presents data on INO-1400 at Society for Immunotherapy of Cancer Conference
Nov 06, 2017: Argos Announces Receipt of Milestone Payment from Lummy
Nov 01, 2017: Janssen to Present Abstracts on Imetelstat at ASH 2017
Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor
Oct 31, 2017: Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
Sep 26, 2017: Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer
Sep 19, 2017: Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Argos Therapeutics Inc, H1 2018
Pipeline by Asterias Biotherapeutics Inc, H1 2018
Pipeline by e-Therapeutics Plc, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by Invectys SA, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by Komipharm International Co Ltd, H1 2018
Pipeline by Mediolanum farmaceutici SpA, H1 2018
Pipeline by Telocyte LLC, H1 2018
Pipeline by TILT Biotherapeutics Ltd, H1 2018
Pipeline by Ultimovacs AS, H1 2018
Pipeline by Vaxon Biotech, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd..1), H1 2018
Loading....